Quick Takeaways Why It Matters? IDEXX is turning Fecal Dx into an even more comprehensive intestinal parasite screen while quietly increasing its value proposition to vets without raising prices. Adding taeniid tapeworms (Taenia and Echinococcus) strengthens the...
Quick Takeaways: Why It Matters? By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing. Bundling mast cell detection at no extra c...
Quick Takeaways: Why It Matters? The DR50 Plus strengthens IDEXX’s imaging ecosystem, giving clinics a premium option that combines lower dose with sharper, AI-optimized images. Dose reduction and fewer retakes can improve staff and patient safety, while tighter ...
Revenue: $5.4M Founded Year: 1982 Market Cap: 54.85M Total Employees: ~70 Headquarters: Maine, United States Stock Exchange: NASDAQ ImmuCell is an animal health company that aims towards the development, manufacturing, and marketing of scientifically-proven products that improve health and...
